EyePoint Pharmaceuticals shares are under pressure as investors weigh a failed Phase 3 trial and controversial data exclusions in the LUGANO study, prompting a formal shareholder investigation.
EyePoint Pharmaceuticals is facing a shareholder investigation following the disclosure that its Phase 3 LUCIA trial for wet AMD failed to meet its primary endpoint. Furthermore, the positive results reported for the LUGANO trial were contingent upon the exclusion of nine patients treated with DURAVYU, raising significant concerns regarding data integrity and the potential for securities litigation.
The investigation focuses on whether the company misled investors regarding the efficacy of its wet AMD trials, specifically following the LUCIA trial failure and the selective exclusion of patients in the LUGANO trial.
The favorable results for the LUGANO trial were dependent on the exclusion of nine patients who received DURAVYU, which has raised questions about the validity of the reported outcomes.
EyePoint Pharmaceuticals faces a shareholder investigation after its LUCIA Phase 3 trial for wet AMD failed to meet its primary endpoint. The company's LUGANO trial results also drew scrutiny, as positive outcomes relied on the exclusion of nine patients treated with DURAVYU, raising concerns over data integrity and potential securities litigation.
The investigation stems from the failure of the LUCIA Phase 3 trial to meet its primary endpoint and concerns regarding the methodology used in the LUGANO trial, which excluded specific patients to achieve favorable results.